Financings Of The Fortnight: How To Read Conflicting Reports On VC Life-Sciences Activity
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by Cleave Biosciences, Anacor Pharmaceuticals, Chimerix and Auris Medical.
You may also be interested in...
Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant
The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.